Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of “Buy” from Analysts

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been given a consensus recommendation of “Buy” by the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $15.97.

Several research firms have recently weighed in on VYGR. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research report on Monday, January 27th. Cantor Fitzgerald began coverage on shares of Voyager Therapeutics in a report on Friday, January 10th. They set an “overweight” rating and a $5.73 price target on the stock. Finally, Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock.

Voyager Therapeutics Price Performance

Shares of Voyager Therapeutics stock opened at $5.53 on Wednesday. The company’s 50 day moving average price is $5.80 and its two-hundred day moving average price is $6.46. The firm has a market capitalization of $302.10 million, a P/E ratio of 7.79 and a beta of 0.91. Voyager Therapeutics has a fifty-two week low of $4.99 and a fifty-two week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same quarter last year, the business posted ($0.59) EPS. On average, analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold 10,778 shares of company stock valued at $58,548 over the last quarter. Insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its stake in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after acquiring an additional 4,098 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Voyager Therapeutics in the third quarter worth $74,000. SG Americas Securities LLC increased its stake in Voyager Therapeutics by 86.7% in the fourth quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock valued at $131,000 after purchasing an additional 10,704 shares in the last quarter. Verition Fund Management LLC acquired a new position in shares of Voyager Therapeutics during the third quarter valued at about $216,000. Finally, Allspring Global Investments Holdings LLC raised its holdings in shares of Voyager Therapeutics by 23.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock valued at $223,000 after purchasing an additional 7,573 shares during the period. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.